Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on Zoledronic Acid Following Denosumab for Osteoporosis Patients

Fast replyRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying osteoporosis, a condition where bones become weak and are more likely to break. The study is examining the effects of a treatment called zoledronic acid, also known as zoledronate. This medication is given as a solution through an intravenous (IV) infusion, which means it is delivered directly into the bloodstream through a vein. The trial will also use a 100 mL isotonic saline solution, which is a standard fluid used in medical treatments.

The purpose of the study is to explore whether multiple infusions of zoledronic acid can help prevent bone loss in patients who have previously been treated with another medication called denosumab. The study will look at how effective zoledronic acid is when given at different times after stopping denosumab. It will also investigate if yearly infusions of zoledronic acid can prevent bone loss after the initial treatment period. Additionally, the study will examine how stopping denosumab affects muscle mass, muscle strength, and insulin sensitivity, which is how the body processes sugar.

Participants in the study will receive treatments over a period of time, and their bone health will be monitored through various tests. These tests will include measuring bone density, which is the strength of the bones, and looking at specific markers in the blood that indicate bone activity. The study aims to provide a better understanding of how to manage bone health in patients with osteoporosis who have been treated with denosumab.

The research process

The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial visit

    Upon joining the clinical trial, you will attend an initial visit. During this visit, your medical history will be reviewed, and you will undergo a physical examination. This is to ensure that you meet the eligibility criteria for the study.

  2. Step 2

    Baseline assessments

    You will undergo a series of baseline assessments. These include a bone density scan, known as a DXA scan, to evaluate your bone health. Blood samples will be collected to measure various biochemical markers related to bone turnover and muscle health.

  3. Step 3

    First infusion

    You will receive your first infusion of zoledronate. This medication is administered through an intravenous (IV) infusion, which means it is given directly into your vein. The infusion contains 5 mg of zoledronate in 100 mL of isotonic saline. This process will take place at a healthcare facility.

  4. Step 4

    Follow-up visits

    You will have follow-up visits at regular intervals. These visits will include additional bone density scans and blood tests to monitor your response to the treatment. The primary focus is to assess changes in your bone mineral density (BMD) at the lumbar spine, total hip, and femoral neck after 12 and 36 months.

  5. Step 5

    Yearly infusions

    You will receive yearly infusions of zoledronate to help maintain bone health. These infusions will be similar to the first one and will be scheduled at specific intervals based on your treatment plan.

  6. Step 6

    Additional assessments

    Throughout the trial, additional assessments will be conducted to evaluate changes in muscle mass and strength, as well as insulin sensitivity. These assessments will help understand the broader effects of the treatment on your overall health.

  7. Step 7

    End of trial

    At the end of the trial, a final evaluation will be conducted. This will include a comprehensive review of your bone health and any changes observed during the study. The results will contribute to understanding the effectiveness of the treatment.

Who can join the trial?

5 criteria

  • Must be a postmenopausal woman (a woman who has not had a menstrual period for at least two years).
  • Must be 40 years old or older.
  • Must have been treated with denosumab (a medication used to treat osteoporosis) for at least two years.
  • The last injection of denosumab must have been received less than five months ago.
  • Must have at least two lumbar vertebrae (bones in the lower spine) that can be evaluated by DXA (a type of scan that measures bone density).

Who cannot join the trial?

2 criteria

  • Patients who are male cannot participate. This study is only for females.
  • Patients who are part of a vulnerable population cannot participate. This means groups of people who might need special protection or care.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Zoledronate

    is a medication used in this clinical trial to help manage bone health in patients who have previously been treated with another medication called denosumab. Zoledronate is given through an infusion, which means it is delivered directly into the bloodstream. The main goal of using zoledronate in this study is to prevent a rapid increase in bone turnover, which can lead to bone loss, after stopping denosumab treatment. The study is exploring whether giving zoledronate at specific times or when bone turnover increases can help maintain bone strength. Additionally, the trial is looking at whether yearly infusions of zoledronate can continue to protect against bone loss after the initial treatment period.

  • Denosumab

    is a medication that was used by patients before they entered this clinical trial. It is typically used to treat osteoporosis by slowing down the process that breaks down bone, helping to maintain bone density and strength. In this study, researchers are interested in understanding what happens to bone health after patients stop taking denosumab. They are also looking at how stopping denosumab affects muscle mass, muscle strength, and how the body processes insulin, which is important for managing blood sugar levels.

What is already known about the treatment

Zoledronate – Zoledronate is administered through an intravenous infusion, meaning it is given directly into a vein. It is currently being studied in clinical trials for its effectiveness in treating osteoporosis, particularly in patients who have previously been treated with another medication called denosumab. The main purpose of zoledronate is to prevent bone loss by slowing down the process of bone breakdown, which is often increased after stopping denosumab. At the molecular level, zoledronate works by inhibiting the activity of cells that break down bone, known as osteoclasts. It is classified as a bisphosphonate, a type of drug that helps to strengthen bones and reduce the risk of fractures.

Investigated diseases

Osteoporosis – Osteoporosis is a condition characterized by weakened bones, making them more prone to fractures. It occurs when the creation of new bone doesn't keep up with the removal of old bone. As the disease progresses, bones become porous and fragile, often without any symptoms until a fracture occurs. Common fracture sites include the hip, spine, and wrist. The disease can lead to a decrease in height over time and a stooped posture. Bone density tests are often used to assess the progression of bone weakening.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase ITrial ID2022-502621-17-00Protocol code01.12.2022Estimated enrolment1 patientSponsorRegion Midtjylland

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).